Phase 2 Breast Cancer Trial, Recruiting NCT07314073 Sponsor: Asan Medical Center Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Recruiting

NCT07314073
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 19 or older, of any race or ethnicity, male or female
  • People who have been newly diagnosed with invasive breast cancer within the past 90 days, confirmed through tissue testing
  • People whose breast cancer has been confirmed through tissue testing to be estrogen receptor-positive and is a lower-grade tumour (grade 1 or 2)
  • People whose cancer has been staged as locally advanced (stage IIIA, IIIB, or IIIC) according to a standard cancer staging system
  • People who have already had, or are scheduled to have, specific scans (chest CT, abdominal CT, and a bone scan) within 90 days before the trial's screening scan
  • People who are generally well enough to carry out basic daily activities, as measured by a standard health performance scale (a score of 2 or lower on the ECOG scale — confirm with trial site if unsure what this means)

Who may not be able to join:

  • People who have not signed, and whose legal representative has not signed, the required consent form
  • People who are currently receiving any systemic treatment for breast cancer, such as chemotherapy or hormone therapy
  • People who have had another invasive cancer (other than certain common skin cancers) within the past two years
  • People whose recent scans (chest CT, abdominal CT, or bone scan) have shown that the cancer has spread to distant parts of the body
  • People who have suspicious findings on scans that may suggest the cancer has spread, but where no further biopsy or follow-up imaging over at least six months has been done to investigate those findings
  • Women who are pregnant or breastfeeding. Women of childbearing potential may still be considered if a pregnancy test taken within 24 hours before the trial scan is negative and they agree to use effective contraception during the trial (confirm details with trial site)
  • People with serious, uncontrolled, or unstable health conditions, such as severe heart failure, a recent heart attack, severe lung disease, or significant kidney or liver disease
  • People who are a relative, student, or otherwise in a dependent relationship with the doctor running the trial
  • People who, in the trial doctor's judgment, would be unable to fully participate in or complete the trial for personal or other reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Hyehyun Jeong, Asan Medical Center

Phone: +82-2-3010-0657

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
24 December 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Patient based detection rate of qualitative [18F]FES PET/CT evaluation for distant metastases

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov